Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › PIONEER 6

PIONEER 6

Semaglutide · T2D at high CV risk

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Semaglutide
Population
T2D at high CV risk
Official title
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Sponsor
Novo Nordisk A/S
Phase
Phase 3
Registry status
completed · 2017-01 → 2018-09
Participants
3183
Registry
NCT02692716

Cardiovascular and kidney outcomes

PIONEER 6 oral semaglutide 14 mg vs placebo · T2D at high CV risk · n = 3183 · 2019 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
First occurrence of CV death (including undetermined causes), nonfatal MI, or nonfatal stroke
0.790.57–1.1161 vs 76verified
Cardiovascular death
Death from cardiovascular causes (including undetermined causes)
0.490.27–0.9215 vs 30verified
All-cause death
Death from any cause
0.510.31–0.8423 vs 45verified
Myocardial infarction
Nonfatal myocardial infarction (first events; fatal MI not separately reported)
1.180.73–1.9037 vs 31verified
Stroke
Nonfatal stroke (first events; fatal stroke not separately reported)
0.740.35–1.5712 vs 16verified
Hospitalisation for heart failure
Heart failure resulting in hospitalization (first events)
0.860.48–1.5521 vs 24verified
Expanded MACE (MACE + HF hosp. + UA)
Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, unstable angina resulting in hospitalization, or heart failure resulting in hospitalization
0.820.61–1.1083 vs 100verified
Hospitalisation for unstable angina
Unstable angina resulting in hospitalization
1.560.60–4.0111 vs 7verified
Verbatim quotes (8)
  • 3-point MACE · Abstract; Results, Cardiovascular Outcomes; Table 2
    Major adverse cardiovascular events occurred in 61 of 1591 patients (3.8%) in the oral semaglutide group and 76 of 1592 (4.8%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.57 to 1.11
  • Cardiovascular death · Abstract; Table 2
    death from cardiovascular causes, 15 of 1591 patients (0.9%) in the oral semaglutide group and 30 of 1592 (1.9%) in the placebo group (hazard ratio, 0.49; 95% CI, 0.27 to 0.92)
  • All-cause death · Abstract; Table 2
    Death from any cause occurred in 23 of 1591 patients (1.4%) in the oral semaglutide group and 45 of 1592 (2.8%) in the placebo group (hazard ratio, 0.51; 95% CI, 0.31 to 0.84)
  • Myocardial infarction · Abstract; Table 2
    nonfatal myocardial infarction, 37 of 1591 patients (2.3%) and 31 of 1592 (1.9%), respectively (hazard ratio, 1.18; 95% CI, 0.73 to 1.90)
  • Stroke · Abstract; Table 2
    nonfatal stroke, 12 of 1591 patients (0.8%) and 16 of 1592 (1.0%), respectively (hazard ratio, 0.74; 95% CI, 0.35 to 1.57)
  • Hospitalisation for heart failure · Results, Cardiovascular Outcomes, paragraph 3; Table 2
    First events of heart failure resulting in hospitalization occurred in 21 of 1591 patients (1.3%) and 24 of 1592 (1.5%), respectively (hazard ratio, 0.86; 95% CI, 0.48 to 1.55).
  • Expanded MACE (MACE + HF hosp. + UA) · Table 2
    Expanded composite outcome§ 83 (5.2) 4.0 100 (6.3) 4.9 0.82 (0.61–1.10)
  • Hospitalisation for unstable angina · Table 2
    Unstable angina resulting in hospitalization 11 (0.7) 0.5 7 (0.4) 0.3 1.56 (0.60–4.01)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: PIONEER 6. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/pioneer-6/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.